WO1996018372A3 - Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules - Google Patents

Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules Download PDF

Info

Publication number
WO1996018372A3
WO1996018372A3 PCT/US1995/016174 US9516174W WO9618372A3 WO 1996018372 A3 WO1996018372 A3 WO 1996018372A3 US 9516174 W US9516174 W US 9516174W WO 9618372 A3 WO9618372 A3 WO 9618372A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic
gene therapy
cationic
therapeutic compositions
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1995/016174
Other languages
French (fr)
Other versions
WO1996018372A2 (en
Inventor
Craig S Siegel
David J Harris
Edward R Lee
Shirley C Hubbard
Seng H Cheng
Simon J Eastman
John Marshall
Ronald K Scheule
Nelson S Yew
Mathieu B Lane
Eric A Rowe
Rebecca G Bagley
Chau-Dung Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27533061&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1996018372(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/352,479 external-priority patent/US5650096A/en
Priority claimed from US08/540,867 external-priority patent/US5747471A/en
Priority to DE69527650T priority Critical patent/DE69527650T2/en
Priority to EP95943769A priority patent/EP0799059B1/en
Priority to DK95943769T priority patent/DK0799059T3/en
Priority to JP8519236A priority patent/JPH10510813A/en
Application filed by Genzyme Corp filed Critical Genzyme Corp
Priority to AT95943769T priority patent/ATE221390T1/en
Priority to AU45161/96A priority patent/AU716706C/en
Publication of WO1996018372A2 publication Critical patent/WO1996018372A2/en
Publication of WO1996018372A3 publication Critical patent/WO1996018372A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or acyl groups; and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile. Novel and highly effective plasmid constructs are also disclosed, including those that are particularly effective at providing gene therapy for clinical conditions complicated by inflammation. Additionally, targeting of organs for gene therapy by intravenous administration of therapeutic compositions is described.
PCT/US1995/016174 1994-12-09 1995-12-08 Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules Ceased WO1996018372A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU45161/96A AU716706C (en) 1994-12-09 1995-12-08 Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
AT95943769T ATE221390T1 (en) 1994-12-09 1995-12-08 CATONIC AMPHIPHILES AND PLASMIDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS
DE69527650T DE69527650T2 (en) 1994-12-09 1995-12-08 CATONIC AMPHIPHILES AND PLASMIDES FOR THE INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS
EP95943769A EP0799059B1 (en) 1994-12-09 1995-12-08 Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
DK95943769T DK0799059T3 (en) 1994-12-09 1995-12-08 Cationic amphiphilic compounds and plasmids for intracellular administration of therapeutic molecules
JP8519236A JPH10510813A (en) 1994-12-09 1995-12-08 Cationic amphiphilic compounds and plasmids for intracellular delivery of therapeutic molecules

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US08/352,479 US5650096A (en) 1994-12-09 1994-12-09 Cationic amphiphiles for intracellular delivery of therapeutic molecules
US434495P 1995-09-26 1995-09-26
US439995P 1995-09-27 1995-09-27
US08/540,867 US5747471A (en) 1994-12-09 1995-10-11 Cationic amphiphiles containing steroid lipophilic groups for intracellular delivery of therapeutic molecules
US08/540,867 1995-10-19
US60/004,344 1995-10-19
US60/004,399 1995-10-19
US08/545,473 US6071890A (en) 1994-12-09 1995-10-19 Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US08/352,479 1995-10-19
US08/545,473 1995-10-19

Publications (2)

Publication Number Publication Date
WO1996018372A2 WO1996018372A2 (en) 1996-06-20
WO1996018372A3 true WO1996018372A3 (en) 1996-09-06

Family

ID=27533061

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/016174 Ceased WO1996018372A2 (en) 1994-12-09 1995-12-08 Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules

Country Status (8)

Country Link
US (1) US6071890A (en)
EP (1) EP0799059B1 (en)
JP (1) JPH10510813A (en)
AT (1) ATE221390T1 (en)
DE (1) DE69527650T2 (en)
DK (1) DK0799059T3 (en)
PT (1) PT799059E (en)
WO (1) WO1996018372A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601872B2 (en) 1998-11-12 2009-10-13 Life Technologies Corporation Transfection reagents

Families Citing this family (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795870A (en) * 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US6383814B1 (en) 1994-12-09 2002-05-07 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US6331524B1 (en) 1994-12-09 2001-12-18 Genzyme Corporation Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy
US5948767A (en) * 1994-12-09 1999-09-07 Genzyme Corporation Cationic amphiphile/DNA complexes
US5939401A (en) * 1994-12-09 1999-08-17 Genzyme Corporation Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
US5962428A (en) * 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US6339173B1 (en) 1996-07-22 2002-01-15 Promega Biosciences, Inc. Amide-based cationic lipids
EP0779361A3 (en) 1995-12-15 1999-11-10 F. Hoffmann-La Roche Ag Truncated form of inhibitory kappa B protein (1kB), recombinant production and uses thereof
FR2744453B1 (en) * 1996-02-05 1998-07-10 Transgene Sa LIPOPOLYAMINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, NUCLEIC ACID TRANSFER VECTORS AND PREPARATION METHOD
DE19607686A1 (en) * 1996-02-29 1997-09-04 Chemicon Lab Gmbh New metabolizable lipopolyamines, their presentation and application
FR2751972B1 (en) * 1996-07-30 1998-09-04 Centre Nat Rech Scient COMPOUNDS RELATED TO THE AMIDINIUM FAMILY, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR APPLICATIONS
PT888379E (en) * 1996-03-01 2001-05-31 Centre Nat Rech Scient ANALOG COMPOUNDS THE FAMILY OF THE AMIDINE COMPOUNDS THAT CONTAIN THEM AND THEIR APPLICATIONS
US6258792B1 (en) 1996-04-12 2001-07-10 University Of Pittsburgh Cationic cholesteryl derivatives containing cyclic polar groups
WO1997039019A1 (en) * 1996-04-12 1997-10-23 University Of Pittsburgh Novel cationic cholesteryl derivatives containing cyclic polar groups
DE69727384T2 (en) * 1996-05-24 2004-11-04 IC-VEC Ltd. POLYCATONIC STERIN DERIVATIVES FOR TRANSFECTION
US5935936A (en) * 1996-06-03 1999-08-10 Genzyme Corporation Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules
US6093816A (en) * 1996-06-27 2000-07-25 Isis Pharmaceuticals, Inc. Cationic lipids
DE19631189A1 (en) * 1996-08-02 1998-02-05 Max Delbrueck Centrum Novel cationic amphiphiles for liposomal gene transfer
US6251433B1 (en) 1996-08-13 2001-06-26 Chiron Corporation Polycationic polymers
US5962429A (en) * 1996-11-22 1999-10-05 University Of Iowa Complexes of adenovirus with cationic molecules
BR9807622A (en) * 1997-02-28 2000-02-15 Boehringer Ingelheim Pharma Self-regulated inflammatory cell apoptosis by gene therapy
US5837283A (en) * 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US5925628A (en) * 1997-03-31 1999-07-20 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5912239A (en) * 1997-04-04 1999-06-15 Genzyme Corporation Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules
US5981275A (en) * 1997-04-14 1999-11-09 Genzyme Corporation Transgene expression system for increased persistence
US6020191A (en) * 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US5948925A (en) * 1997-05-06 1999-09-07 Genzyme Corporation Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
US5952516A (en) * 1997-05-08 1999-09-14 Genzyme Corporation Cationic amphiphiles containing multiplesteroid lipophilic groups
US5942634A (en) * 1997-05-09 1999-08-24 Genzyme Corporation Cationic amphiphiles for cell transfections
AU733310C (en) 1997-05-14 2001-11-29 University Of British Columbia, The High efficiency encapsulation of charged therapeutic agents in lipid vesicles
US6835395B1 (en) 1997-05-14 2004-12-28 The University Of British Columbia Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
AU7490098A (en) * 1997-05-15 1998-12-08 Genzyme Corporation Cationic amphiphile formulations
FR2765877B1 (en) * 1997-07-10 1999-09-10 Oreal COMPOSITION COMPRISING AN AQUEOUS DISPERSION OF LIPID VESICLES BASED ON CHOLESTERYL CHAIN CARBAMATES, USE IN PARTICULAR IN COSMETICS AND NEW COMPOUNDS
WO1999002190A1 (en) * 1997-07-11 1999-01-21 Genzyme Corporation Organ-specific targeting of cationic amphiphile/retinoblastoma encoding dna complexes for gene therapy
US6197332B1 (en) 1997-08-13 2001-03-06 Chiron Corporation Lipid-conjugated polyamide compounds and related compositions and methods thereof
CA2299429C (en) 1997-08-13 2010-04-20 Biontex Laboratories Gmbh New lipopolyamines,their preparation and the use thereof
IL135578A0 (en) 1997-10-29 2001-05-20 Genzyme Corp Compositions and methods for treating lysosomal storage disease
ATE550042T1 (en) 1997-11-20 2012-04-15 Vical Inc TREATMENT OF CANCER USING CYTOKINE-EXPRESSING POLYNUCLEOTIDES AND COMPOSITIONS THEREOF
DE69940774D1 (en) 1998-06-17 2009-06-04 Idm Pharma Inc HLA-Binding PEPTIDES AND ITS USES
AU8818398A (en) 1998-08-21 2000-03-14 Felix Frey Conjugates of dna interacting groups with steroid hormones for use as nucleic acid transfection agent
DE19956568A1 (en) 1999-01-30 2000-08-17 Roland Kreutzer Method and medicament for inhibiting the expression of a given gene
ES2251134T3 (en) * 1999-06-08 2006-04-16 Gentium S.P.A. USE OF COMPLEXES BETWEEN CATIONIC LIPOSOMES AND POLYDESOXIRRIBONUCLEOTIDOS AS MEDICINES.
DE19944262A1 (en) * 1999-09-15 2001-03-29 Cardiogene Gentherapeutische S Pharmaceutical composition in the form of a nucleic acid-lipid complex, its production and use in gene therapy
US7829693B2 (en) * 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
WO2001042200A1 (en) * 1999-12-10 2001-06-14 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
GB0015624D0 (en) * 2000-06-26 2000-08-16 Nat Cancer Centre Materials and methods relating to improved gene delivery
DK1299727T3 (en) 2000-07-12 2009-06-15 Agensys Inc Hitherto unknown tumor antigen suitable for diagnosis and treatment of bladder, ovarian, lung, and renal cancer types
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
WO2002072790A2 (en) 2001-03-14 2002-09-19 Myriad Genetics, Inc Tsg101-gag interaction and use thereof
US7294511B2 (en) * 2001-03-22 2007-11-13 Chromos Molecular Systems, Inc. Methods for delivering nucleic acid molecules into cells and assessment thereof
AU2002367566B2 (en) * 2001-11-20 2008-10-16 Duke University Interfacial biomaterials
US20030216315A1 (en) 2002-02-13 2003-11-20 Duke University Modulation of immune response by non-peptide binding stress response polypeptides
PT1515752E (en) 2002-06-19 2009-03-05 Univ Health Network Ace2 activation for treatment of heart, lung and kidney disease and hypertension
CA2500715A1 (en) 2002-10-03 2004-04-15 Epimmune Inc. Hla binding peptides and their uses
US8067371B2 (en) * 2003-05-09 2011-11-29 The Trustees Of Columbia University In The City Of New York RAGE G82S-related methods and compositions for treating inflammatory disorders
EP1638919B1 (en) * 2003-06-18 2012-09-26 Biolab Ltd. Sphingolipids polyalkylamines conjugates
US7608699B2 (en) 2003-12-29 2009-10-27 Rockefeller University Synthetic nuclear localization signal derived from lentiviral integrase and methods of use thereof
US20060014289A1 (en) * 2004-04-20 2006-01-19 Nastech Pharmaceutical Company Inc. Methods and compositions for enhancing delivery of double-stranded RNA or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells
US20060051396A1 (en) 2004-06-16 2006-03-09 Affinergy, Inc. Biofunctional coatings
WO2006133333A2 (en) 2005-06-07 2006-12-14 The Rockefeller University Stimulation of pancreatic b cell proliferation
CA2656548A1 (en) 2005-06-30 2007-01-11 Whitehead Institute Progenitor cells and uses thereof
NZ569138A (en) 2005-12-15 2012-06-29 Centre Nat Rech Scient Cationic oligonucleotides automated methods for preparing same and their uses
US7807624B2 (en) * 2006-01-11 2010-10-05 Affinergy, Inc. Methods and compositions for promoting attachment of cells of endothelial cell lineage to medical devices
EP1844772A1 (en) * 2006-04-06 2007-10-17 Polyplus-Transfection SA Compositions for transfection of oligonucleotides active for gene silencing and their biological and therapeutical applications
WO2007150069A2 (en) 2006-06-23 2007-12-27 Myriad Genetics, Inc. Dpyd gene variants and use thereof
WO2008089403A2 (en) 2007-01-18 2008-07-24 Genzyme Corporation Oligosaccharides comprising an aminooxy group and conjugates thereof
JP2011502484A (en) 2007-11-01 2011-01-27 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ HLA-DR binding peptides and their use
FR2925491B1 (en) * 2007-12-19 2010-09-03 Oz Biosciences Sas NEW CLASSES OF CATIONIC LIPIDS FOR THE TRANSPORT OF ACTIVE AGENTS IN CELLS
EP2077119A1 (en) * 2007-12-21 2009-07-08 Apeiron Biologics Forschungs- und Entwicklungsgesellschaft M.B.H. Treatment of fibrosis and liver diseases
FR2926818B1 (en) * 2008-01-30 2012-04-06 Centre Nat Rech Scient CATIONIC siRNA, SYNTHESIS AND USE FOR RNA INTERFERENCE
EP2123256A1 (en) * 2008-05-19 2009-11-25 Ruhr-Universität Bochum Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer
WO2010042815A2 (en) * 2008-10-09 2010-04-15 Duke University Vhh antibody fragments for use in the detection and treatment of cancer
TW201021853A (en) * 2008-11-17 2010-06-16 Enzon Pharmaceuticals Inc Releasable cationic lipids for nucleic acids delivery systems
CN102369023A (en) 2008-12-16 2012-03-07 建新公司 Oligosaccharide-protein conjugates
CA2766907A1 (en) 2009-07-06 2011-01-13 Novartis Ag Self replicating rna molecules and uses thereof
CA2768186A1 (en) 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
US8518405B2 (en) 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
EP3318248B1 (en) 2009-12-01 2019-04-10 Translate Bio, Inc. Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
EP2569633B1 (en) 2010-05-14 2016-02-10 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
WO2012051211A2 (en) 2010-10-11 2012-04-19 Novartis Ag Antigen delivery platforms
US9011292B2 (en) 2010-11-01 2015-04-21 Nike, Inc. Wearable device assembly having athletic functionality
CN103380113B (en) * 2010-11-15 2018-03-30 生命科技公司 Amine-containing transfection reagents and methods of making and using the same
US9376486B2 (en) 2010-12-14 2016-06-28 National University Of Singapore Human monoclonal antibody with specificity for Dengue virus serotype 1 E protein and uses thereof
WO2012103361A1 (en) 2011-01-26 2012-08-02 Novartis Ag Rsv immunization regimen
MX2013012345A (en) 2011-04-22 2015-05-07 Genzyme Corp Modified acid alpha glucosidase with accelerated processing.
CA2835644C (en) 2011-05-13 2021-06-15 Novartis Ag Pre-fusion rsv f antigens
RU2013154295A (en) 2011-06-08 2015-07-20 Шир Хьюман Дженетик Терапис, Инк. COMPOSITIONS OF LIPID NANOPARTICLES AND METHODS FOR DELIVERY OF mRNA
EP2729165B1 (en) 2011-07-06 2017-11-08 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
CA2841047A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
RU2014118727A (en) 2011-10-11 2015-11-20 Новартис Аг RECOMBINANT SELF-REPLICING POLYCISTRON RNA MOLECULES
US20140348863A1 (en) 2011-10-12 2014-11-27 Alessia Bianchi Cmv antigens and uses thereof
EP2785370B1 (en) 2011-12-02 2021-07-21 Rhode Island Hospital Vaccine for falciparum malaria
WO2013185067A1 (en) 2012-06-08 2013-12-12 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
US20150140068A1 (en) 2012-07-06 2015-05-21 Novartis Ag Immunogenic compositions and uses thereof
US9783490B2 (en) * 2012-12-18 2017-10-10 The Secretary Of State For Health Antimicrobial compounds, their synthesis and applications thereof
CN109045294A (en) 2013-01-10 2018-12-21 思齐乐 Influenza virus immunization Immunogenic Compositions and its application
JP6586075B2 (en) 2013-03-14 2019-10-02 トランスレイト バイオ， インコーポレイテッド Method for purifying messenger RNA
RS57739B1 (en) 2013-03-14 2018-12-31 Translate Bio Inc Cftr mrna compositions and related methods and uses
EP2983702A2 (en) 2013-04-07 2016-02-17 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
CN106413811A (en) 2013-10-22 2017-02-15 夏尔人类遗传性治疗公司 Mrna therapy for argininosuccinate synthetase deficiency
JP6506749B2 (en) 2013-10-22 2019-04-24 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド MRNA therapy for phenylketonuria
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
KR20230076867A (en) 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 Combination therapy with neoantigen vaccine
US9850269B2 (en) 2014-04-25 2017-12-26 Translate Bio, Inc. Methods for purification of messenger RNA
EP3169310A1 (en) 2014-07-15 2017-05-24 Life Technologies Corporation Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
CA2956161A1 (en) 2014-07-23 2016-01-28 Ohio State Innovation Foundation Methods and compositions related to antibody fragments that bind to tumor-associated glycoprotein 72 (tag-72)
EP3031822A1 (en) 2014-12-08 2016-06-15 Novartis AG Cytomegalovirus antigens
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
EP3047856A1 (en) 2015-01-23 2016-07-27 Novartis AG Cmv antigens and uses thereof
IL294183B2 (en) 2015-05-20 2023-10-01 Dana Farber Cancer Inst Inc Shared neoantigens
TW202241500A (en) 2015-06-09 2022-11-01 美商博德研究所有限公司 Formulations for neoplasia vaccines and methods of preparing thereof
EP3347380B1 (en) 2015-09-11 2024-09-25 Nascent Biotech, Inc. Enhanced delivery of drugs to the brain
ES2970865T3 (en) 2015-12-16 2024-05-31 Gritstone Bio Inc Identification, manufacture and use of neoantigens
JP2019513373A (en) 2016-03-31 2019-05-30 ネオン セラピューティクス， インコーポレイテッド Neo antigen and method of using the same
AU2017254477A1 (en) 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
EA201991747A1 (en) 2017-02-27 2020-06-04 Транслейт Био, Инк. NEW CODON-OPTIMIZED CFTR mRNA
CA3058807A1 (en) 2017-04-03 2018-10-11 Biontech Us Inc. Protein antigens and uses thereof
CN106995384B (en) * 2017-04-21 2018-12-11 郑州大学 Amphipathic antibacterial peptide mimics of dialkyl cationic with antibacterial activity and preparation method thereof
MX2019013752A (en) 2017-05-16 2020-07-20 Translate Bio Inc Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr.
WO2018213803A1 (en) 2017-05-19 2018-11-22 Neon Therapeutics, Inc. Immunogenic neoantigen identification
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
CN111630602A (en) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 Reduced junctional epitope presentation of neoantigens
MX2020007077A (en) 2018-01-04 2020-10-28 Iconic Therapeutics Inc ANTI-TISSUE FACTOR ANTIBODIES, ANTIBODY-DRUG CONJUGATES AND RELATED METHODS.
WO2019232208A1 (en) * 2018-05-30 2019-12-05 Translate Bio, Inc. Cationic lipids comprising a steroidal moiety
KR102950141B1 (en) 2018-08-24 2026-04-07 트랜슬레이트 바이오 인코포레이티드 Method for purifying messenger RNA
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020106946A1 (en) 2018-11-21 2020-05-28 Translate Bio, Inc. TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
WO2021014385A1 (en) 2019-07-24 2021-01-28 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
JP7711045B2 (en) 2019-09-02 2025-07-22 アンスティテュ・クリー Immunotherapy targeting tumor neoantigen peptides
EP4031662A1 (en) 2019-09-20 2022-07-27 Translate Bio, Inc. Mrna encoding engineered cftr
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
WO2021078910A1 (en) 2019-10-22 2021-04-29 Institut Curie Immunotherapy targeting tumor neoantigenic peptides
US20230212243A1 (en) 2020-05-12 2023-07-06 Institut Curie Neoantigenic Epitopes Associated with SF3B1 Mutations
US12030912B2 (en) * 2020-05-15 2024-07-09 Brigham Young University Cationic steroidal antimicrobial compounds with urethane linkages
MA71659A (en) * 2020-08-06 2025-05-30 Modernatx, Inc. COMPOSITIONS FOR DELIVERING PAYLOAD MOLECULES TO THE RESPIRATORY TRACT EPITHELIUM
JP2024501482A (en) 2020-12-14 2024-01-12 ビオンテック ユーエス インコーポレイテッド Tissue-specific antigens for cancer immunotherapy
EP4277933A4 (en) 2021-01-14 2024-12-11 Senti Biosciences, Inc. SECRETABLE PAYLOAD REGULATION
KR20240006721A (en) 2021-03-11 2024-01-15 엥스띠뛰 퀴리 Membrane-transforming neoantigen peptide
AU2022233019A1 (en) 2021-03-11 2023-09-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Tumor neoantigenic peptides
WO2023076598A1 (en) * 2021-10-29 2023-05-04 Modernatx, Inc. Lipid amines
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
US20250302930A1 (en) 2022-03-24 2025-10-02 Institut Curie Immunotherapy targeting tumor transposable element derived neoantigenic peptides in glioblastoma
CN117003808A (en) * 2022-04-28 2023-11-07 北京科兴中维生物技术有限公司 A cationic lipid compound and its preparation method and use
CN119563028A (en) 2022-05-12 2025-03-04 尚威天成信使核糖核酸治疗公司 Synthetic self-amplifying mRNA molecules with secreted antigens and immunomodulators
CN118845700A (en) * 2023-04-29 2024-10-29 康希诺(上海)生物研发有限公司 Lipid nanoparticles for delivering nucleic acid drugs and preparation method and use thereof
WO2025064470A1 (en) 2023-09-19 2025-03-27 Regeneron Pharmaceuticals, Inc. Viral peptides and uses thereof
WO2025136809A2 (en) 2023-12-19 2025-06-26 Regeneron Pharmaceuticals, Inc. Foxp3 peptides and uses thereof
WO2025178991A1 (en) 2024-02-21 2025-08-28 Regeneron Pharmaceuticals, Inc. Splicing factor gene mutation-associated neoantigenic peptides and uses thereof
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof
EP4702988A1 (en) 2024-08-28 2026-03-04 Biotechnology Assets S.A. Combination product for the treatment of leishmaniasis
WO2026062222A1 (en) 2024-09-20 2026-03-26 Institut Curie Novel protein isoforms and uses

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988000824A1 (en) * 1986-07-28 1988-02-11 Liposome Technology, Inc. Liposomes with enhanced retention on mucosal tissue
US4971803A (en) * 1985-04-08 1990-11-20 California Institute Of Technology Lamellar vesicles formed of cholesterol derivatives
US5004737A (en) * 1989-09-22 1991-04-02 Pacific Chemical Co., Ltd. Quaternary ammonium-substituted sterol derivatives
EP0490379A2 (en) * 1990-12-13 1992-06-17 BERLIN-CHEMIE Aktiengesellschaft Diamino acid derivatives and pharmaceutical compositions
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
WO1994005624A1 (en) * 1992-08-28 1994-03-17 Life Technologies, Inc. Cationic lipids
WO1994020520A1 (en) * 1993-03-10 1994-09-15 Magainin Pharmaceuticals Inc. Steroid derivatives, pharmaceutical compositions containing them, and their use as antibiotics or disinfectants

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
FR2645866B1 (en) * 1989-04-17 1991-07-05 Centre Nat Rech Scient NEW LIPOPOLYAMINES, THEIR PREPARATION AND THEIR USE
US4958013A (en) * 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5908635A (en) * 1994-08-05 1999-06-01 The United States Of America As Represented By The Department Of Health And Human Services Method for the liposomal delivery of nucleic acids
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
DE59507224D1 (en) * 1994-12-28 1999-12-16 Max Delbrueck Centrum New cholesterol derivative for liposomal gene transfer

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4971803A (en) * 1985-04-08 1990-11-20 California Institute Of Technology Lamellar vesicles formed of cholesterol derivatives
WO1988000824A1 (en) * 1986-07-28 1988-02-11 Liposome Technology, Inc. Liposomes with enhanced retention on mucosal tissue
US5004737A (en) * 1989-09-22 1991-04-02 Pacific Chemical Co., Ltd. Quaternary ammonium-substituted sterol derivatives
EP0490379A2 (en) * 1990-12-13 1992-06-17 BERLIN-CHEMIE Aktiengesellschaft Diamino acid derivatives and pharmaceutical compositions
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
WO1994005624A1 (en) * 1992-08-28 1994-03-17 Life Technologies, Inc. Cationic lipids
WO1994020520A1 (en) * 1993-03-10 1994-09-15 Magainin Pharmaceuticals Inc. Steroid derivatives, pharmaceutical compositions containing them, and their use as antibiotics or disinfectants

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
K. R. PATEL ET AL: "Modification of vesicle surfaces with amphiphilic sterols. Effect on permeability and in vivo tissue distribution.", BIOCHIMICA ET BIOPHYSICA ACTA. BIOMEMBRANES, vol. 814, no. 2, 11 April 1985 (1985-04-11), pages 256 - 264, XP000573084 *
K. S. MOORE ET AL: "Squalamine: an aminosterol antibiotic from the shark.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 90, no. 4, February 1993 (1993-02-01), WASHINGTON US, pages 1354 - 1358, XP000572356 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601872B2 (en) 1998-11-12 2009-10-13 Life Technologies Corporation Transfection reagents
US9358300B2 (en) 1998-11-12 2016-06-07 Life Technologies Corporation Transfection reagents

Also Published As

Publication number Publication date
WO1996018372A2 (en) 1996-06-20
DK0799059T3 (en) 2002-11-25
AU4516196A (en) 1996-07-03
ATE221390T1 (en) 2002-08-15
JPH10510813A (en) 1998-10-20
DE69527650T2 (en) 2003-02-27
AU716706B2 (en) 2000-03-02
EP0799059A1 (en) 1997-10-08
EP0799059B1 (en) 2002-07-31
DE69527650D1 (en) 2002-09-05
PT799059E (en) 2002-11-29
US6071890A (en) 2000-06-06

Similar Documents

Publication Publication Date Title
WO1996018372A3 (en) Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
WO1998002190A3 (en) Cationic amphiphile/dna complexes
DE69832293T2 (en) PREPARATIONS FOR THE DELIVERY OF NEGATIVELY LOADED MOLECULES
CA2270396C (en) Cationic reagents for transfection
US6858225B2 (en) Lipid-encapsulated polyanionic nucleic acid
JP6126072B2 (en) Processes and compositions for efficient delivery by liposomes in therapy to suppress gene expression
DE69736385T2 (en) CATIONIC LIPID AND RECEPTOR LIGAND FACILITATED GIVING OF BIOLOGICALLY ACTIVE MOLECULES
US20060147514A1 (en) Method for introducing antisense oligonucleotides into eucaryotic cells
JP2007505954A5 (en)
WO1997000965A3 (en) A lipidic vector for nucleic acid delivery
DE69636032D1 (en) PLASMIDE FOR THE ADMINISTRATION OF NUCLEIC ACIDS AND METHOD OF USE
KR20220092273A (en) Lipid nanoparticles comprising mannose or uses thereof
KR20130062953A (en) Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same
AU2008230379B2 (en) Prompt nucleic acid delivery carrier composition
AU2008325504B2 (en) Nucleic acid complex and nucleic acid delivery composition
KR100448298B1 (en) Glucocotricoid enhancement of gene expression
Walker et al. Chemistry and cellular aspects of cationic facial amphiphiles
WO2001042424A3 (en) Sphingolipid-containing cationic liposomes for topical delivery of bioactive material
EP2113247A2 (en) High efficiency encapsulation of nucleic acids in lipid vesicles
EP2060262B1 (en) Composition comprising at least one nucleosidic moiety as a therapeutic agent, and ckc
EP1724254A2 (en) Novel compositions for the delivery of negatively charged molecules
WO2009063081A2 (en) Composition comprising at least one nucleosidic moiety as a therapeutic agent, and ckc.
MXPA00001855A (en) Novel compositions for the delivery of negatively charged molecules

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1995943769

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2205968

Country of ref document: CA

Ref country code: CA

Ref document number: 2205968

Kind code of ref document: A

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1995943769

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1995943769

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995943769

Country of ref document: EP